# Lieneke F.M. Ariëns

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lieneke-f-m-ariens/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,096 |
| Field | Dermatology and Skin Diseases |
| h-index | 14 |
| i10-index | 15 |
| Last Known Institution | Utrecht University |
| OpenAlex ID | https://openalex.org/A5018321480 |
| ORCID iD | 0000-0001-5256-0091 |
| Works | 19 |

## Researcher papers

- [Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab–clinical characteristics and treatment](https://scholariq.org/papers/conjunctivitis-occurring-in-atopic-dermatitis-patients-treated-with-dupilumab/)
- [Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis](https://scholariq.org/papers/goblet-cell-scarcity-and-conjunctival-inflammation-during-treatment-with/)
- [Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry](https://scholariq.org/papers/dupilumab-is-very-effective-in-a-large-cohort-of-difficult-to-treat-adult-atopic/)
- [Barriers and Facilitators to eHealth Use in Daily Practice: Perspectives of Patients and Professionals in Dermatology](https://scholariq.org/papers/barriers-and-facilitators-to-ehealth-use-in-daily-practice-perspectives-of/)
- [Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry](https://scholariq.org/papers/dupilumab-shows-long-term-effectiveness-in-a-large-cohort-of-treatment/)
- [Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment](https://scholariq.org/papers/economic-burden-of-adult-patients-with-moderate-to-severe-atopic-dermatitis/)
- [Dupilumab facial redness: Positive effect of itraconazole](https://scholariq.org/papers/dupilumab-facial-redness-positive-effect-of-itraconazole/)
- [Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis](https://scholariq.org/papers/long-term-follow-up-and-treatment-outcomes-of-conjunctivitis-during-dupilumab/)
- [Two‐year drug survival of dupilumab in a large cohort of difficult‐to‐treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry](https://scholariq.org/papers/two-year-drug-survival-of-dupilumab-in-a-large-cohort-of-difficult-to-treat/)
- [Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy](https://scholariq.org/papers/dupilumab-in-atopic-dermatitis-rationale-latest-evidence-and-place-in-therapy/)

## Researcher topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Contact Dermatitis and Allergies](https://scholariq.org/topics/contact-dermatitis-and-allergies/)
- [Urticaria and Related Conditions](https://scholariq.org/topics/urticaria-and-related-conditions/)

## Researcher university

- [Utrecht University](https://scholariq.org/institutions/utrecht-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.